Literature DB >> 6782926

Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.

E A Neuwelt, J T Diehl, L H Vu, S A Hill, A J Michael, E P Frenkel.   

Abstract

Reversible transient osmotic blood-brain barrier disruption was used to increase drug delivery to the brain. Methotrexate was administered 33 times to six patients with brain tumors after barrier disruption. No permanent complications were seen. Serial enhanced computed tomographic (CT) scans and quantification by CT tomographic number indicated that disruption increased drug delivery to the tumor and immediate surrounding brain. Neuroradiologic evaluation showed that drug in the tumor persisted longer after barrier disruption than when delivered without disruption. The concentration of methotrexate in spinal fluid did not correlate with the degree of barrier disruption measured by CT and radionuclide scans. In one patient an anatomic variation in the circle of Willis resulted in barrier disruption extending into the posterior fossa without ill effect. Osmotic blood-brain barrier disruption appears to be a safe procedure in man, able to increase drug delivery to both malignant brain tumors and surrounding brain parenchyma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6782926     DOI: 10.7326/0003-4819-94-4-449

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

Review 1.  Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.

Authors:  Linfeng Wu; Xiaoxun Li; Dileep R Janagam; Tao L Lowe
Journal:  Pharm Res       Date:  2013-08-31       Impact factor: 4.200

2.  Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.

Authors:  E A Neuwelt; S A Dahlborg
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

3.  Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high-dose chemotherapy for aggressive non-Hodgkin's lymphoma.

Authors:  N L Gilchrist; J Caldwell; I D Watson; D Cunningham; G J Forrest; M Soukop; M Stewart; W Fitch
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Chemotherapy of malignant gliomas.

Authors:  Y Ushio; T Hayakawa; H Hasegawa; K Yamada; N Arita
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

5.  Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J Dennery; D Nundy; J Prior; V Montpetit; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

6.  Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.

Authors:  Lilyana Angelov; Nancy D Doolittle; Dale F Kraemer; Tali Siegal; Gene H Barnett; David M Peereboom; Glen Stevens; John McGregor; Kristoph Jahnke; Cynthia A Lacy; Nancy A Hedrick; Edna Shalom; Sandra Ference; Susan Bell; Lisa Sorenson; Rose Marie Tyson; Marianne Haluska; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Canonical WNT signaling components in vascular development and barrier formation.

Authors:  Yulian Zhou; Yanshu Wang; Max Tischfield; John Williams; Philip M Smallwood; Amir Rattner; Makoto M Taketo; Jeremy Nathans
Journal:  J Clin Invest       Date:  2014-08-01       Impact factor: 14.808

8.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier.

Authors:  E A Neuwelt; P A Barnett; D D Bigner; E P Frenkel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

9.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J M Dennery; R Belanger; J Gerin-Lajoie; V Montpetit; D Nundy; J Prior; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

10.  The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80.

Authors:  M N Azmin; J F Stuart; A T Florence
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.